Dopamine is an aryl hydrocarbon receptor agonist.

Area of Science:

• Biochemistry
• Pharmacology
• Cell Biology

Background:

• Tryptophan and phenylalanine metabolites are known activators of the aryl hydrocarbon receptor (AhR).
• Serotonin and carbidopa have demonstrated AhR activation in previous studies.
• Understanding novel AhR agonists is crucial for drug development and disease research.

Purpose of the Study:

• To investigate the aryl hydrocarbon receptor (AhR) activity of the neuroactive hormone dopamine.
• To determine if dopamine induces drug-metabolizing enzymes, similar to other known AhR agonists.
• To compare the AhR activity and cellular effects of dopamine and carbidopa in various cell lines.

Main Methods:

• Treatment of colon, glioblastoma, pancreatic cancer (BxPC3, Panc1) cells with dopamine and carbidopa.
• Measurement of drug-metabolizing enzyme induction (CYP1A1, CYP1B1, UGT1A1).
• Assessment of aryl hydrocarbon receptor (AhR) activity and cellular cytotoxicity.

Main Results:

• Dopamine induced CYP1A1, CYP1B1, and UGT1A1 in colon and glioblastoma cells.
• Carbidopa showed similar enzyme induction in these cell lines.
• AhR activity varied by cell type; carbidopa activated AhR in BxPC3 cells, while dopamine showed minimal activity in pancreatic cancer cells.
• Carbidopa's induction and cytotoxicity were observed only at high concentrations (100 µM) in BxPC3 cells.

Conclusions:

• Dopamine is identified as an aryl hydrocarbon receptor (AhR)-active compound, similar to serotonin and tryptophan metabolites.
• Dopamine's ability to induce drug-metabolizing enzymes suggests a role in cellular signaling pathways.
• Differential AhR activity of dopamine and carbidopa across cell lines warrants further investigation.